Amazon hires insurance exec for joint healthcare venture

Amy Baxter | | Health Exec | Management
Amazon logo

Photo by Anna Shvets via Pexels

Dana Gelb Safran, a well-known health insurance executive, has been hired by the healthcare joint venture between Amazon, Berkshire Hathaway and J.P. Morgan, CNBC reported.

The hire comes after the joint venture, which aims to improve healthcare and lower costs for the employees of the three companies, has made several grabs from the healthcare industry.

Safran was formerly a chief performance measurement and improvement officer at Blue Cross Blue Shield of Massachusetts, CNBC reported. Her new title will be head of measurement, and she is expected to start at the beginning of next year.

Her experience suggests the new healthcare JV will have a data-driven focus and could elevate the entity’s exposure in the insurance space, CNBC predicted. She is also the first female executive hired by the JV. 

“Having an exec who worked at a health plan could also be useful if the group decides to take on traditional insurers,” CNBC reported.

See the full story below:

The health care venture from Amazon, Berkshire and JP Morgan just hired its fir…

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.